. There is a pressing need to identify novel mechanisms and therapeutic targets for AD using human model systems, such as human neurons.
AD is pathologically characterized by the formation of intracellular neurofibrillary tangles (NFTs), comprised of hyperphosphorylated tau protein, and extracellular amyloid plaques, comprised of Aβ peptides 1 . ApoE4, the presence of which is the major genetic risk factor for AD 3, 4 , is found to be associated with increases in both pathologies 1 . In general, ApoE4 increases AD risk and lowers the age of onset in a gene-dose-dependent manner 5 . Of note, the lifetime risk estimate of developing AD by age 85 is ~65% in people with two copies of the APOE-ε4 allele, which encodes apoE4, but only ~10% in people with two copies of the APOE-ε3 allele, which encodes ApoE3 6 . This notable difference highlights the importance of ApoE4 in the pathogenesis of AD.
Human ApoE3 and ApoE4 differ from each another only at one amino acid residue at position 112. ApoE3, the common isoform, has Cys112, whereas ApoE4 has Arg112 1, 7, 8 . Structurally, APOE has two domains: the amino-terminal domain and the carboxylterminal domain, which contain the receptor-binding region and the lipid-binding region, respectively. The two domains are linked by a structurally flexible hinge region. Interaction between the carboxy-and amino-terminal domains, called domain interaction, is a unique biophysical property of ApoE4 1, 7, 8 . In ApoE4, domain interaction occurs as a result of the formation of a salt bridge between Arg61 and Glu255, owing to the effect of Arg112. This interaction occurs to a much less extent in ApoE3, because the side chain of Arg61 adopts a different conformation owing to Cys112 that results in a less accessible side chain conformation for formation of a salt bridge with Glu255 1, 7, 8 . Domain interaction has been suggested to be a molecular basis for ApoE4's detrimental effects in AD pathogenesis; consequently, it has been pursued as a drug target to identify small-molecule structure correctors capable of converting ApoE4 to ApoE3 both structurally and functionally 1, 7, 8 . Studies in animal models and postmortem human tissues have provided key insights into the pathogenesis of AD 1, 2, 9 . However, mouse models of AD do not recapitulate many AD features, and postmortem human brain tissues have characteristics of end-stage disease that may not be present at earlier stages 1, 2, 9 . Until recently, studies of the cellular and molecular mechanisms of AD have been hindered by the lack of access to live human neurons. Now, induced pluripotent stem cells (iPSCs) derived from human somatic cells with AD-linked mutations or polymorphisms, together with gene-editing techniques, are promising in vitro models for studying disease pathogenesis in relevant cell types, including human neurons [10] [11] [12] [13] [14] [15] .
Here we analyzed AD-related phenotypes of cultured neurons derived from human iPSC (hiPSC) lines of different APOE genotypes, including gene-edited isogenic and APOE-deficient lines. We also tested the effects of gene editing to convert APOE-ε4 into APOE-ε3 and of a small-molecule structure corrector to render ApoE4 ApoE3-like. Our data demonstrate that ApoE4 induced AD-related pathological phenotypes, due to a gain of toxic effects, specifically in human neurons, which could be dramatically ameliorated by treatment with a small-molecule ApoE4-structure corrector.
Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector
. ApoE4/4 neurons secreted > 2-fold more Aβ 40 and Aβ 42 into the culture medium than ApoE3/3 neurons, both in individual lines ( Supplementary Fig. 2g,h ) and as shown by mean values (Fig. 1n,o) . The ApoE4/4 neurons also secreted greater amounts of soluble amyloid-β precursor protein (sAPP) into the medium (Fig. 1p,q) , suggesting increased processing of APP. Of note, the levels of full-length APP protein (Fig. 1r,s) and of the APP mRNA ( Fig. 1t) were similar in ApoE4/4 and ApoE3/3 neurons, as determined by western blot and qRT-PCR analysis, respectively, suggesting that ApoE4 did not alter APP expression in human neurons. Notably, the ratios of TUJ1 to actin were similar in ApoE3/3 and ApoE4/4 neuronal cultures (Fig. 1r,u) , which was indicative of comparable neuronal populations in amount and purity.
Because it has been reported that in APOE-ε3-and APOE-ε4-knock-in mice expressing human APP with mutations that cause familial AD, ApoE4 seems to reduce Aβ clearance and stimulate Aβ deposition in the brain without affecting Aβ production 23 , we wondered whether the difference in ApoE4's effect on Aβ production between our human neuron study and the previously reported mouse data reflected species difference in APOE regulation of Aβ metabolism. To address this question, we also generated mouse iPSC (miPSC) lines from fibroblasts of the APOE-ε3 KI mice and the APOE-ε4 KI mice, differentiated them into neurons in culture for 7-8 weeks and measured Aβ secretion from the miPSC-derived neurons in culture. Clearly, there were no significant differences in both Aβ 40 and Aβ 42 levels in the culture medium of neurons derived from the ApoE3/3 miPSC and ApoE4/4 miPSC lines ( Supplementary Fig. 3 ). These data indicate the species difference in APOE isoform regulation of Aβ metabolism, i.e., ApoE4 stimulates Aβ production in human neurons but not in mouse neurons.
Increased p-tau levels in ApoE4/4 neurons are independent of high levels of Aβ. It has been suggested that Aβ accumulation could increase phosphorylation and accumulation of tau 24, 25 . To assess the potential causal relationship between increased Aβ production and increased p-tau levels, we treated ApoE4/4 neurons with an inhibitor of β -secretase (OM99-2) or of γ -secretase (compound E) for 1 week to inhibit Aβ production 10 . Aβ 40 and Aβ 42 levels in the culture medium decreased by 60-75% (OM99-2) or by > 95% (compound E) (Fig. 2a,b) . Notably, despite these drastic reductions of Aβ levels, p-tau levels were unaffected in ApoE4/4 neurons, as shown by western blot analysis with monoclonal antibodies AT8 and AT180 (Fig. 2c-e ).
ApoE4 causes GABAergic neuron degeneration or loss in hiPSCderived neuronal culture. Immunofluorescence staining revealed significantly fewer GABA + neurons derived from ApoE4/4 hiPSCs than from ApoE3/3 hiPSCs, both in individual lines ( Supplementary Fig. 2i ) and as shown by mean values (Fig. 3a-c) . Levels of GAD2 and GAD1 (GABAergic neuron markers; also known as GAD65 and GAD67, respectively) were lower in neuronal cultures derived from ApoE4/4-hiPSCs than in those derived from ApoE3/3 hiPSCs, both in individual lines ( Supplementary Fig. 2j ) and as shown by mean values (Fig. 3d,e) . Immunostaining revealed no significant difference in the numbers of GABA + neurons at early time points (within 4 weeks) in culture between ApoE4/4 hiPSCs and ApoE3/3 hiPSCs (relative to the ApoE3/3 hiPSCs; ApoE3/3: 1 ± 0.11 (mean ± s.e.m.), n = 5 fields with total of 570 GABA + neurons counted; ApoE4/4: 0.98 ± 0.14 (mean ± s.e.m.), n = 8 fields with total of 894 GABA + neurons counted), suggesting that the detrimental effect of ApoE4 on GABAergic neurons in culture was not a developmental effect. The decrease in GABAergic neuron numbers occurred during the late stage of neuronal differentiation of ApoE4/4-hiPSCs, suggesting that ApoE4 induced GABAergic neurodegeneration or loss. Of note, ApoE3/3 hiPSCs and ApoE4/4 hiPSCs had similar efficiencies in generating TBR1
+ glutamatergic neurons and TH + dopaminergic neurons in culture ( Supplementary Fig. 4 ), suggesting a specific detrimental effect of ApoE4 on GABAergic neurons. Furthermore, ~60% of GABAergic neurons derived from ApoE4/4 hiPSCs, but only ~30% of those derived from ApoE3/3 hiPSCs, were immunopositive for p-tau (Fig. 3f-h ). 2.5 P = 0.0004 P = 0.0208 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001
Fig. 1 | Human ApoE4/4 neurons generate more APOE fragments, have higher p-tau levels and produce more Aβ than human ApoE3/3 neurons. a-c, Representative western blot analysis (a) and quantification of full-length APOE in lysates (intracellular) (b) or the medium (secreted) (c) from neurons that were derived from ApoE3/3 hiPSCs (E3/3) or ApoE4/4 hiPSCs (E4/4). Actin was used as a loading control. In b, values were normalized to those of E3/3 (E3/3, n = 23 biologically independent samples (n = 9 from ApoE3/3-A; n = 8 from ApoE3/3-B; n = 6 from ApoE3/3-C); E4/4, n = 20 biologically independent samples (n = 6 from ApoE4/4-A; n = 6 from ApoE4/4-B; n = 8 from ApoE4/4-C)). In c, values were normalized to those of E3/3 (E3/3, n = 15 biologically independent samples (n = 6 from ApoE3/3-A; n = 6 from ApoE3/3-B; n = 3 from ApoE3/3-C); E4/4, n = 9 biologically independent samples (n = 3 from ApoE4/4-A; n = 3 from ApoE4/4-B; n = 3 from ApoE4/4-C)). d,e, Representative western blot analysis (d) and quantification (e) of full-length APOE and of APOE fragments in lysates from E3/3 and E4/4 neurons. Values were normalized to those of E3/3 (E3/3, n = 13 biologically independent samples (n = 3 from ApoE3/3-A; n = 5 from ApoE3/3-B; n = 5 from ApoE3/3-C); E4/4, n = 14 biologically independent samples (n = 3 from ApoE4/4-A; n = 5 from ApoE4/4-B; n = 6 from ApoE4/4-C)). f-j, Western blot analysis (f) and quantification of p-tau in lysates of E3/3 and E4/4 neurons with the p-tau-specific monoclonal antibodies AT8 (g), AT180 (h), PHF1 (i) and AT270 (j). In f, Tau5 and TUJ1 were used for loading control and normolization. In g, values were normalized to those of E3/3 (E3/3, n = 31 biologically independent samples; E4/4, n = 25 biologically independent samples). In h, values were normalized to those of E3/3 (E3/3, n = 22 biologically independent samples (n = 7 from ApoE3/3-A; n = 7 from ApoE3/3-B; n = 8 from ApoE3/3-C); E4/4, n = 18 biologically independent samples (n = 6 from ApoE4/4-A; n = 4 from ApoE4/4-B; n = 8 from ApoE4/4-C)). In i, values were normalized to those of E3/3 (E3/3, n = 17 biologically independent samples (n = 4 from ApoE3/3-A; n = 6 from ApoE3/3-B; n = 7 from ApoE3/3-C); E4/4, n = 25 biologically independent samples (n = 8 from ApoE4/4-A; n = 8 from ApoE4/4-B; n = 9 from ApoE4/4-C)). In j, values were normalized to those of E3/3 (E3/3, n = 23 biologically independent samples (n = 10 from ApoE3/3-A; n = 10 from ApoE3/3-B; n = 3 from ApoE3/3-C); E4/4, n = 17 biologically independent samples (n = 10 from ApoE4/4-A; n = 4 from ApoE4/4-B; n = 3 from ApoE4/4-C)). k-m, Representative images showing immunostaining of MAP2 and p-tau (using AT8 and PHF1) in E3/3 and E4/4 neuronal cultures (k) and quantification of the percentage of MAP2 + neurons that were also positive for p-tau, as detected by using AT8 (l) or PHF1 (m), in E3/3 and E4/4 neuronal cultures (E3/3, n = 12 (n = 12 fields with total of 594 MAP2 + neurons counted for AT8; n = 12 fields with total of 945 MAP2 + neurons counted for PHF1); E4/4, n = 12 (n = 12 fields with total of 526 MAP2 + neurons counted for AT8; n = 12 fields with total of 1,030 MAP2 + neurons counted for PHF1). Scale bar, 50 μ m. n,o, Aβ 40 (n) and Aβ 42 (o) levels in the medium from E3/3 and E4/4 neuronal cultures (E3/3, n = 23 biologically independent samples (n = 4 from ApoE3/3-A; n = 7 from ApoE3/3-B; n = 12 from ApoE3/3-C); E4/4, n = 21 biologically independent samples (n = 5 from ApoE4/4-A; n = 4 from ApoE4/4-B; n = 12 from ApoE4/4-C)). p,q, Representative western blot analysis (p) and quantification (q) of sAPP in the culture medium of E3/3 and E4/4 neurons. Values were normalized to those of E3/3 (E3/3, n = 15 biologically independent samples (n = 6 from ApoE3/3-A; n = 6 from ApoE3/3-B; n = 3 from ApoE3/3-C); E4/4, n = 6 biologically independent samples (n = 2 from ApoE4/4-A; n = 2 from ApoE4/4-B; n = 2 from ApoE4/4-C). r,s, Representative western blot analysis (r) and quantification (s) of APP with the 22C11 monoclonal antibody in lysates of E3/3 and E4/4 neurons. TUJ1 was used for normalization. Values were normalized to those of E3/3 (E3/3, n = 11 biologically independent samples (n = 4 from ApoE3/3-A; n = 4 from ApoE3/3-B; n = 3 from ApoE3/3-C); E4/4, n = 19 biologically independent samples (n = 3 from ApoE4/4-A; n = 8 from ApoE4/4-B; n = 8 from ApoE4/4-C)). t, Quantification of APP mRNA levels by qRT-PCR in E3/3 and E4/4 neurons. Values are normalized to those of E3/3 (E3/3, n = 12 biologically independent samples (n = 4 from ApoE3/3-A; n = 4 from ApoE3/3-B; n = 4 from ApoE3/3-C); E4/4, n = 12 biologically independent samples (n = 4 from ApoE4/4-A; n = 4 from ApoE4/4-B; n = 4 from ApoE4/4-C)). u, TUJ1/actin ratios in lysates of E3/3 and E4/4 neurons. Values were normalized to those of E3/3 (E3/3, n = 11 biologically independent samples (n = 4 from ApoE3/3-A; n = 4 from ApoE3/3-B; n = 3 from ApoE3/3-C); E4/4, n = 19 biologically independent samples (n = 3 from ApoE4/4-A; n = 8 from ApoE4/4-B; n = 8 from ApoE4/4-C)). Throughout, data are expressed as mean ± s.e.m. Differences between groups were determined with the unpaired two-sided t-test.
To further determine the detrimental effects of ApoE4 on GABAergic interneurons, we adapted a protocol of differentiating hiPSCs to medial ganglionic eminence (MGE) cells, which are GABAergic progenitors, and then to mature GABAergic interneurons in culture [26] [27] [28] . The purity of MGE cells and of GABAergic interneurons were 96.03 ± 1.25% and 93.15 ± 0.99% (mean ± s.e.m.), respectively, as determined by anti-NKX2.1 (a MGE cell marker) and anti-GABA immunostaining and flow cytometry analysis ( Supplementary Fig. 5a-d) . Western blot analysis with anti-p-tau (AT8 and PHF1) revealed significantly increased p-tau levels in ApoE4/4 GABAergic neurons, as compared to that in ApoE3/3 GABAergic neurons, after 5 weeks of culture, whereas there were no significant differences after 1 and 2 weeks of culture ( Fig. 3i-k) . Furthermore, immunostaining with p-tau-specific antibodies (AT8 and PHF1) also revealed that 70-100% more GABAergic neurons derived from ApoE4/4 MGE cells than from ApoE3/3 MGE cells were immunopositive for p-tau ( Supplementary Fig. 5e,f) . Notably, p-tau accumulated in degenerating (beading) axons, as determined by anti-p-tau (PHF1) and anti-total-tau double immunostaining, in ApoE4/4 GABAergic neurons, but not in ApoE3/3 GABAergic neurons, at 5 weeks of culture (Fig. 3l,m) . Similar to that observed in brains from individuals with AD, p-tau also mislocalized to dendrites of ApoE4/4 GABAergic neurons, which did not seem to happen as much in ApoE3/3 GABAergic neurons, as revealed by anti-p-tau (PHF1) and anti-MAP2 double immunostaining ( Supplementary  Fig. 5h,i) . Quantification of cells positive for expression of both caspase-3 and GABA suggested that there was significantly (P < 0.05) more apoptotic cell death of ApoE4/4 GABAergic neurons than of ApoE3/3 GABAergic neurons ( Supplementary Fig. 5g ). Taken together, these data demonstrate clearly that ApoE4 induces human GABAergic neuron degeneration or death in culture.
Gene editing reveals the specificity of ApoE4 in eliciting AD-related pathologies in human ApoE4/4 neurons. To determine whether the AD-related pathologies in ApoE4/4 neurons were specifically induced by ApoE4, we used gene editing to generate an isogenic ApoE3/3 hiPSC line from the ApoE4/4 hiPSC-A line ( Supplementary Fig. 6a ) 29 . As in the parental line, the isogenic ApoE3/3 hiPSC line (iE3/3) had normal expression of genes involved in pluripotency ( Supplementary Fig. 6b ,c) and a normal karyotype ( Supplementary Fig. 6d ), and it generated normal neural stem cells, which expressed SOX2, nestin and FOXG1 ( Supplementary  Fig. 6e ,f), and developed into mature neurons ( Supplementary  Fig. 6g ). Of note, DNA sequencing analyses revealed no off-target effects of the gene-editing process, at least on some major AD-related genes (Supplementary Table 2 ).
Next we assessed AD-related pathologies in neurons derived from the iE3/3 hiPSC line. The conversion from ApoE4 to ApoE3 had marked phenotypic effects. It increased the levels of fulllength APOE (Fig. 4a ) and decreased the levels of APOE fragments in neuronal lysates ( Fig. 4b ) and the secretion of Aβ 40 and Aβ 42 into the culture medium (Fig. 4c,d ). The levels of p-tau were decreased ( Fig. 4e-g ), and there were fewer p-tau + neurons ( Fig. 4i-k and Supplementary Fig. 7a-c) . The conversion also rescued the degeneration or loss of GABAergic neurons in ApoE4/4 hiPSC neuronal cultures, as shown by significant increases in GAD67 levels (Fig. 4e,h ) and in the number of GABA + neurons ( Fig. 4l-n) . The iE3/3 hiPSC cultures also had significantly fewer p-tau + GABAergic neurons (Supplementary Fig. 7d -i) than the parental ApoE4/4 hiPSC cultures. Likewise, GABAergic neurons generated from the iE3/3-hiPSC-derived MGE cells also had decreased levels of p-tau and of axonal degeneration, as compared to the GABAergic neurons derived from the parental ApoE4/4-hiPSC-derived MGE cells ( Supplementary Fig. 8 ). In sum, conversion of ApoE4 to ApoE3 by gene editing abolished the detrimental effects of ApoE4 and resulted in cellular phenotypes similar to those of ApoE3-expressing cells, strongly suggesting that the AD-related pathologies in ApoE4/4 neurons were induced specifically by ApoE4.
Reintroduction of different APOE isoforms into APOE-deficient human neurons reveals a gain of toxic effects from ApoE4.
To determine whether ApoE4 induced a loss of function or a gain of toxic effects in human neurons, we also generated a hiPSC line from a subject with an APOE deficiency (APOE -/-) 30 . The APOE Neurons derived from the APOE -/-hiPSCs and the iE3/3 hiPSCs secreted similar levels of Aβ 40 and Aβ 42 into the medium (Fig. 5c,d ). Furthermore, APOE -/-hiPSCs and the iE3/3 hiPSCs generated sim- biologically independent samples per group; OM99-2, n = 3 biologically independent samples per group; Copd-E, n = 3 biologically independent samples per group). c-e, Representative western blot analysis of p-tau (c) and quantification of p-tau with the monoclonal antibodies AT8 (d) and AT180 (e) in lysates of E4/4 neurons after treatment with vehicle (control), OM99-2 or compound E for 1 week. Values were normalized to those of the control treatment (n = 8 biologically independent samples per group). Throughout, data are expressed as mean ± s.e.m. Differences among groups were determined with one-way analysis of variance (ANOVA) followed by Tukey's multiple-comparison test; ***P < 0.001 versus the E4/4 control. ilar numbers of GABA + neurons ( Fig. 5e-g ). Thus, the phenotypes of APOE-null neurons were similar to those of ApoE3/3 neurons.
To further test the potential gain of toxicity conferred by ApoE4, we transfected neurons derived from the APOE -/-hiPSCs with lentiviral cDNA constructs encoding ApoE3 or ApoE4. The transfected neurons expressed similar levels of ApoE3 and ApoE4 protein (Fig. 5h,i) ; however, the cells expressing ApoE4 had higher p-tau levels (Fig. 5h ,j) and fewer GABA + neurons (Fig. 5m ,n), and they produced more Aβ 40 and Aβ 42 (Fig. 5o,p) , than the neurons expressing ApoE3 or the controls (Fig. 5j -l,n-p). Notably, treatment of the APOE -/--hiPSC-derived neurons with purified recombinant human ApoE3 or ApoE4 did not signifi- Values were normalized to those of E3/3 (E3/3, n = 36 fields (n = 16 from ApoE3/3-A; n = 12 from ApoE3/3-B; n = 8 from ApoE3/3-C; with total of 9,325 GABA + neurons counted); E4/4, n = 32 fields (n = 12 from ApoE4/4-A; n = 12 from ApoE4/4-B; n = 8 from ApoE4/4-C; with total of 3,433 GABA + neurons counted). d,e, Representative western blot analysis (d) and quantification, relative to TUJ1 expression, (e) of GAD65 and GAD67 in lysates of E3/3 and E4/4 neurons. Values were normalized to those of E3/3 (E3/3, n = 54 biologically independent samples (n = 20 from ApoE3/3-A; n = 25 from ApoE3/3-B; n = 9 from ApoE3/3-C); E4/4, n = 35 biologically independent samples (n = 14 from ApoE4/4-A; n = 12 from ApoE4/4-B; n = 9 from ApoE4/4-C)). f-h, Images showing immunostaining for both GABA and p-tau (using AT8) in E3/3 (f) and E4/4 (g) neuronal cultures and quantification of the percentage of p-tau
+ cells (h) (E3/3, n = 12 fields (n = 4 from ApoE3/3-A; n = 4 from ApoE3/3-B; n = 4 from ApoE3/3-C; with total of 352 GABA + neurons counted); E4/4, n = 12 fields (n = 4 from ApoE4/4-A; n = 4 from ApoE4/4-B; n = 4 from ApoE4/4-C; with total of 144 GABA + neurons counted)). Scale bars, 25 μ m. i-k, Representative western blot analysis of p-tau (using AT8 and PHF1) in lysates of pure E3/3 and E4/4 GABAergic neurons (i) and quantification of p-tau by using AT8 (j) or PHF1 (k). Values were normalized to those of E3/3 (AT8: E3/3, n = 10 biologically independent samples (n = 5 from ApoE3/3-A; n = 5 from ApoE3/3-B); E4/4, n = 10 biologically independent samples (n = 5 from ApoE4/4-A; n = 5 from ApoE4/4-B); PHF1: E3/3, n = 10 biologically independent samples (n = 5 from ApoE3/3-A; n = 5 from ApoE3/3-B); E4/4, n = 10 biologically independent samples (n = 5 from ApoE4/4-A; n = 5 from ApoE4/4-B)). l,m, Representative images showing immunostaining for p-tau (using PHF1; green) and total tau (red) in E4/4 (l) and E3/3 (m) GABAergic neurons. The experiments were repeated independently three times with similar results. Scale bars, 25μ m. Throughout, data are expressed as mean ± s.e.m. Differences between groups were determined by an unpaired two-sided t-test (c,e,h) or a two-way ANOVA followed with Sidak's multiple comparisons test (j,k); **P < 0.01; ***P < 0.001.
cantly alter Aβ production ( Supplementary Fig. 10e,f) , suggesting that the effect of ApoE4 on Aβ production depended on the endogenous expression of APOE. Together, these findings strongly suggest that ApoE4 confers a gain of toxic effects in hiPSC-derived neurons.
The gain of toxic effects of ApoE4 is neuron specific. Although astrocytes are the major source of APOE production in brains 1, 7 , neurons can also produce APOE, especially when under stress or in response to injuries 1, 7, [31] [32] [33] . We confirmed that hiPSC-derived neurons, including glutamatergic and GABAergic neurons, did , n = 8 biologically independent samples per group; iE3/3, n = 6 biologically independent samples per group). e-h, Representative western blot analysis for p-tau (using PHF1 and AT8) and for GAD67 (e) and quantification of p-tau levels, as detected by monoclonal antibody PHF1 (f) or AT8 (g), or of GAD67 levels (h) in lysates of E4/4 and iE3/3 neurons. Values were normalized to those of E4/4 (ptau: E4/4, n = 8 biologically independent samples per group; iE3/3, n = 6 biologically independent samples per group; GAD67: E4/4, n = 14 biologically independent samples; iE3/3, n = 20 biologically independent samples). i-k, Representive images showing immunostaining for p-tau (using AT8) and MAP2 in E4/4 (i) and iE3/3 (j) neurons and quantification of the percentage of p-tau , n = 6 fields, with a total of 3,897 GABA + neurons counted). Scale bar, 50 μ m. h-j, Representative western blot analyses of APOE expression and p-tau levels (using PHF1) in lysates of APOE-null neurons that were transfected with a control lentiviral vector ( + Con), an ApoE3-expressing lentiviral construct ( + E3) or an ApoE4-expressing lentiviral construct ( + E4) (h) and quantification of the full-length APOE (i) and p-tau (j) in lysates from the indicated neurons. Values were normalized to those of + E3 neurons (i) or to those of + Con neurons (j) (n = 3 biologically independent samples per group). k-n, Representative images showing immunostaining of GABA in + Con (k), + E3 (l) and + E4 (m) neurons and quantification of GABA + cells per field (n). Values were normalized to those of + Con neurons ( + Con, n = 8 fields, with a total of 1,104 GABA + neurons counted; + E3, n = 8 fields, with a total of 1,234 of GABA + neurons counted; + E4, n = 8 fields, with a total of 637 GABA + neurons counted). Scale bars, 50 μ m. o,p, Aβ 40 (o) and Aβ 42 (p) levels in the culture medium of + Con, + E3 and + E4 neurons. Values were normalized to those of + Con neurons (n = 3 biologically independent samples per group). Throughout, data are expressed as mean ± s.e.m. Differences between groups were determined by an unpaired two-sided t-test (a-d,g,i) or a one-way ANOVA followed with Tukey's multiple-comparison test (j,n-p). *P < 0.05; **P < 0.01. express APOE in culture (which likely represents a 'stress' condition), as determined by staining for both APOE and a neuronal marker ( Supplementary Fig. 11 ). Because our neuronal culture was highly pure, with a negligible number of astrocytes ( Supplementary  Fig. 12a,c,e) , the neuronal APOE was unlikely taken up from the astrocyte-secreted pool.
To further determine whether human-astrocyte-derived ApoE4 also had detrimental effects in hiPSC-derived neurons, we differentiated hiPSCs with different APOE genotypes into mature astrocytes ( Supplementary Fig. 12b,d,e) and collected the astrocyteconditioned medium (ACM), which had the secreted ApoE3 or ApoE4. The neurons in culture that were derived from the APOE -/-hiPSCs were treated for 1 week with the ACM containing 0.35 nM (12 ng/ml) or 1.47 nM (50 ng/ml) of either ApoE3 or ApoE4 (Supplementary Fig. 13 ). These concentrations of APOE were similar to (0.35 nM) or 3-to 4-fold higher than (1.47 nM) those in brain interstitial fluid (ISF) of mice 34 , which largely reflect the pool of astrocyte-secreted APOE in brains. Clearly, treatment with the ACM containing the ApoE4 at either concentrations did not significantly affect the levels of p-tau (as assessed by AT8 and PHF1) and GAD67 (GABAergic neuron marker), as well as the production and/ or secretion of Aβ 40 and Aβ 42 , in APOE -/--hiPSC-derived neuron culture ( Supplementary Fig. 13 ). Thus, human-astrocyte-derived ApoE4 does not confer detrimental effects in human neurons (at least for tau phosphorylation, GABAergic neuron degeneration and Aβ production), supporting the conclusion that the gain of toxic effects of ApoE4 is neuron specific. Fig. 14a) 1,35 and identified small-molecule structure correctors that render ApoE4 ApoE3-like both structurally and functionally ( Supplementary  Fig. 14b ) [36] [37] [38] . In ApoE4/4-hiPSC-derived neurons, treatment with one of the structure correctors, PH002 ( Supplementary Fig. 14b ) [36] [37] [38] , significantly decreased ApoE4 fragment levels (Fig. 6a,b) , increased GABAergic neuron numbers (Fig. 6c ) and GAD67 levels (Fig. 6d,f) , reduced p-tau levels (Fig. 6d,e) , and decreased Aβ 40 and Aβ 42 production and/or secretion (Fig. 6g,h ) in a dose-dependent manner (Fig. 6i-l) . Thus, the detrimental effects of ApoE4 in hiPSC-derived neurons could be ameliorated by a small-molecule ApoE4 structure corrector. Of note, treatment of APOE -/--hiPSC-derived neurons with different concentrations of PH002 did not show any significant effects on Aβ production and/or secretion or on p-tau or GAD67 levels ( Supplementary Fig. 14c-f) , indicating that the efficacy of PH002 depended on the presence of ApoE4.
Detrimental effects of ApoE4 in hiPSC-derived neurons are ameliorated by a small-molecule structure corrector. We previously reported ApoE4 domain interaction (Supplementary

Discussion
Here we assessed the phenotypes of cultured neurons that were derived from multiple hiPSC lines of different APOE genotypes, including gene-edited isogenic and APOE-deficient lines. We found that ApoE4 specifically induced AD-related pathologies, including the increase in APOE fragmentation, tau phosphorylation and Aβ production, as well as the degeneration or loss of GABAergic neurons. Notably, these AD-related pathologies were associated with a neuron-specific gain of toxic effects of ApoE4 and were ameliorated by treatment with a small-molecule structure corrector that renders ApoE4 structurally and functionally similar to ApoE3 [36] [37] [38] . Lower levels of ApoE4, as compared to those of ApoE3, have been reported in the brains of mice in which the genes encoding human ApoE4 or ApoE3 were knocked in 39 and in samples of human brain and cerebrospinal fluid 1 . Indeed, we found that cultured human neurons have ~35% less intracellular ApoE4 than ApoE3 and secrete ~60% less ApoE4 than ApoE3. Consequently, the ratio of intracellular APOE to secreted APOE was more than 20% higher in ApoE4/4 neurons, suggesting that ApoE4 tended to be retained inside neurons. These findings might reflect a prolonged retention time of ApoE4 in the endoplasmic reticulum and the Golgi apparatus, as reported in cultured rat neuronal cells 37 . APOE fragments accumulate in the brains of mice with neuron-specific expression of ApoE4 and in patients with AD who carried the gene encoding ApoE4 17, 18 . However, our study shows for the first time in cultured human neurons that ApoE4 is more susceptible than ApoE3 to proteolytic cleavage, generating more neurotoxic fragments.
In humans and transgenic mice, ApoE4 is associated with increased Aβ accumulation and amyloid plaque formation in the brain 1, 40 . In APOE-ε3-and APOE-ε4-knock-in mice expressing human APP with mutations that cause familial AD, ApoE4 seems to reduce Aβ clearance and stimulate Aβ deposition, especially during the initial seeding stage of plaque formation 41, 42 , in the brain without affecting Aβ production 23 . We found that the endogenously expressed ApoE4 significantly stimulated Aβ production in cultured human neurons, likely by enhancing APP processing. Thus, ApoE4's effects on Aβ production are species specific. Notably, conversion of ApoE4 to ApoE3 by gene editing significantly lowered Aβ production, consistent with a specific effect of ApoE4. This observation highlights the phenotypic differences between mouse and human cellular models of AD. Those differences must be recognized to understand why so many AD drugs in development failed in human clinical trials, even though they worked very well in mouse models of AD, and to develop drugs that are more likely to be effective in patients with AD.
It has recently been reported that ApoE4 enhances APP expression, which leads to increased Aβ production, in a pure excitatory human neuron culture system 43 . However, we did not observe a similar effect of ApoE4 on APP expression in a mixed human neuronal culture system. This could be due to the following differences between the two experimental systems. First, the induced excitatory neurons were generated by artificially expressing a transcription factor, NGN2, in hiPSCs, without inhibitory neurons in the culture 43 .
As reported in previous in vitro and in vivo studies, Aβ production is regulated by neuronal activity-increasing neuronal activity stimulates Aβ production and secretion 44, 45 . Thus, in this pure excitatory neuronal culture, in which there are no inhibitory neurons to control the activity, the Aβ production pathway and its regulation could be altered in a way that might not be physiologically relevant. In contrast, in the mixed neuronal culture the presence of inhibitory neurons balances neuronal activities, as seen under a physiological condition, making Aβ production more physiologically controlled. Second, in the pure excitatory neuron study, conditioned medium containing 294 nM (10 μ g/ml) ApoE3 or ApoE4 was collected from transfected HEK293 cells and was then used to treat pure excitatory neurons in culture 43 . This APOE concentration is > 800-fold higher than the physiological concentrations of APOE (∼ 0.35 nM) in mouse brain ISF 34 . In addition, it has been reported that HEK293-cell-secreted APOE differs from astrocytes-secreted APOE, including their poor lipidation status, self-aggregation, and inability to bind well with the low-density-lipoprotein (LDL) receptor 46 . In our study, however, we used astrocyte-secreted ApoE3 or ApoE4 at concentrations (0.35 or 1.47 nM) similar to those in mouse brain ISF 34 . ApoE4 has been associated with AD-related tau pathologies both in humans and in transgenic and gene-targeted mice 1, 7, 17, 18 . Our study shows that ApoE4, in fact, increases p-tau levels in cultured human neurons. ApoE4/4 neurons in culture were positive for multiple p-tau-specific monoclonal antibodies (e.g., AT8, AT180, AT270 and PHF1), suggesting hyperphosphorylation of tau. Furthermore, p-tau in ApoE4/4 human neurons was largely mislocalized to the soma and dendrites, as seen in brains from individuals with AD. Again, conversion of ApoE4 to ApoE3 by gene editing significantly lowered p-tau levels, consistent with a specific effect of ApoE4. It has been suggested that Aβ accumulation leads to increase in phosphorylation and accumulation of tau 24, 25 . However, we showed that treatment of ApoE4/4 human neurons with a β -secretase or a γ -secretase inhibitor drastically reduced Aβ 40 and Aβ 42 levels without altering p-tau levels at all. These findings strongly suggest that ApoE4 induces p-tau accumulation in an Aβ -independent manner in human neurons, at least in culture. In line with this conclusion, a recent study suggests that ApoE4 also has an Aβ -independent and gain-of-toxicity effect on tau-mediated neurodegeneration in a tauopathy model of mice expressing mutant human tau 47 .
ApoE4 also had a detrimental effect on GABAergic neurons in hiPSC-derived neuronal cultures. This was especially true in relatively pure GABAergic neuronal cultures derived from hiPSCs and was consistent with observations in brains from mice in which the gene encoding human ApoE4 was knocked in [48] [49] [50] [51] . Hyperphosphorylated tau was found to be accumulated in axons of GABAergic neurons, which led to axonal degeneration, and it also mislocalized to neuronal dendrites, as seen in the brains of Values were normalized to those of untreated E4/4 neurons (E3/3, n = 5 biologically independent samples; E4/4, n = 5 biologically independent samples; E4/4 + DMSO, n = 6 biologically independent samples; E4/4 + PH002, n = 6 biologically independent samples). c, Quantification of GABA + cells per field in E3/3, E4/4, E3/3 + DMSO, E4/4 + DMSO and E4/4 + PH002 neuronal cultures. Values were normalized to those of the E3/3 neuronal cultures (E3/3, n = 6 fields, with a total of 3,071 GABA + neurons counted; E4/4, n = 6 fields, with a total of 1,223 GABA + neurons counted; E3/3 + DMSO, n = 3 fields, with a total of 1,358 GABA + neurons counted; E4/4 + DMSO, n = 3 fields, with a total of 511 GABA + neurons counted; E4/4 + PH002, n = 3 fields, with a total of 1,077 GABA + neurons counted). d-f, Representative western blot analyses of p-tau (using AT8) and GAD67 (d) and quantification of p-tau (e) and GAD67 (f) levels in lysates from E3/3, E4/4, E4/4 + DMSO and E4/4 + PH002 neurons. Values were normalized to those of E3/3 neurons (p-tau: E3/3, n = 6 biologically independent samples; E4/4, n = 7 biologically independent samples; E3/3 + DMSO, n = 5 biologically independent samples; E4/4 + DMSO, n = 8 biologically independent samples; E4/4 + PH002, n = 8 biologically independent samples; GAD67: E3/3, n = 7 biologically independent samples; E4/4, n = 7 biologically independent samples; E3/3 + DMSO, n = 5 biologically independent samples; E4/4 + DMSO, n = 8 biologically independent samples; E4/4 + PH002, n = 6 biologically independent samples). g,h, Aβ 40 (g) and Aβ 42 (h) levels in the culture medium of E3/3, E4/4, E4/4 + DMSO and E4/4 + PH002 neurons (n = 4 biologically independent samples per group for E3/3 and E4/4; n = 3 biologically independent samples per group for E4/4 + DMSO and E4/4 + PH002). i-l, Dose effects of PH002 treatment on Aβ 40 (i), Aβ 42 (j), p-tau (using PHF1) (k) and GAD67 (l) levels in culture medium or cell lysates of E4/4 neurons (n = 4 biologically independent samples per group). DMSO treatment was used as a control. Throughout, data are expressed as mean ± s.e.m. Differences among groups were determined by a one-way ANOVA followed with Tukey's multiple-comparison test. *P < 0.05; **P < 0.01; ***P < 0.001; versus E4/4 or E4/4 + DMSO (b,c,e-h) or versus E4/4 + DMSO (i-l).
individuals with AD. These effects, too, were ApoE4 specific, as they were abolished by conversion of ApoE4 to ApoE3. GABAergic interneuron loss and neuronal hyperactivity due to loss of inhibitory tone have been observed in mice in which the gene encoding ApoE4 was knocked in 48, 49, 52 . Notably, GABAergic interneuron deficits in these mice correlate with spatial learning and memory impairment 48, 49 , and deletion of the APOE-ε4 gene in GABAergic interneurons in loxP-flanked (floxed) APOE-ε4-knock-in mice restores normal learning and memory, and it rescues ApoE4-induced impairment of hippocampal network activity 53, 54 . Thus, ApoE4-induced GABAergic interneuron degeneration and/or dysfunction could contribute significantly to dementia in patients with AD.
A long-standing question has been whether the detrimental effects of ApoE4 in AD pathogenesis reflect a loss of normal function or a gain of toxic effects 1, 55 . Studies in animals suggest both possibilities 1, 55 , and it has been difficult to address this question in humans. Our hiPSC-derived neuron model of APOE deficiency and the complementary experiments of reintroducing ApoE4 into the APOE-null human neurons strongly argue for a gain of toxic effects of ApoE4 in AD pathogenesis, at least for its effects on tau phosphorylation, Aβ production and GABAergic neuron degeneration. This conclusion is consistent with the report of an APOE-deficient patient in which it was detailed that neurocognitive studies failed to demonstrate any defects 30 . This information has critical implications for developing drugs targeting ApoE4-reducing ApoE4 expression might be an attractive strategy.
Finally, our findings in hiPSC-derived neurons provide a proof of concept that correcting the pathogenic conformation of ApoE4 is a viable therapeutic approach for ApoE4-related AD 1, 8, [36] [37] [38] . Treatment of ApoE4/4-hiPSC-derived neurons with the ApoE4 structure corrector PH002 [36] [37] [38] ameliorated the detrimental effects of ApoE4 on tau phosphorylation, Aβ production and GABAergic neuron degeneration in a dose-dependent manner. These findings warrant further development of ApoE4 structure correctors and, ultimately, testing in clinical trials.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41591-018-0004-z.
Generating and characterizing hiPSC and miPSC lines with different APOE genotypes. hiPSC lines were generated as described 16, 17 from skin fibroblasts of subjects with different APOE genotypes or an APOE deficiency (Supplementary Table 1 ). miPSC lines were generated from fibroblasts that were derived from mice that had human APOE-ε3 or human APOE-ε4 knocked in, using a similar protocol 16, 17 . The hiPSCs were maintained under feeder-free conditions in mTeSR1 medium (STEMCELL Technologies) or on irradiated SNL (a mouse fibrobast STO cell line) feeder cells in hES cell medium consisting of Dulbecco's modified Eagle's medium (DMEM) with nutrient mixture F12 (DMEM/F12) with 20% knockout serum replacement (Life Technologies, a Thermo Fisher Scientific Brand), 2 mM glutamine, 0.1 mM nonessential amino acids (all from Life Technologies), 4 ng/ ml recombinant human basic fibroblast growth factor (bFGF) (PeproTech) and 0.1 mM 2-mercaptoethanol 56 . hiPSCs were routinely passaged at 1:2-1:4 by brief treatment with Accutase (Millipore) and scraping. The hiPSC protocol was approved by the Committee on Human Research at the University of California, San Francisco.
Generating and characterizing isogenic ApoE3/3 hiPSC lines by zinc-finger nuclease (ZFN)-mediated gene editing. To generate isogenic ApoE3/3 hiPSC lines, we dissociated the parental ApoE4/4 hiPSCs with Accutase (Millipore) and placed 2 × 10 6 cells in nucleofection solution (Lonza) containing 4 μ g of the APOE-ZFNencoding mRNA pair together with 5 μ g of the ApoE3-encoding donor DNA. A specific pair of six-finger ZFNs that were engineered to target a region around Arg112 of the ApoE4-encoding allele was designed and prepared by Sigma. The ZFNs bound (uppercase letters) and cut (lowercase letters) the following sequence on the APOE gene: CGGGCACGGCTGTCCAAGgagctGCAGGCGGCGCAGGCCCG. The mixture was transferred to a cuvette and nucleofected with Nucleofector II (Lonza) at Nucleofector setting A-23 and the Human Stem Cell Nucleofector Kit I, as reported 29 . Nucleofected cells were quickly transferred to 500 μ l of prewarmed (37 °C) hES cell medium (STEMCELL Technologies) , incubated at 37 °C for 5 min and plated at 1 × 10 6 cells per well in an irradiated SNL-coated 6-well plate containing hES medium supplemented with 10 μ M ROCK inhibitor (ROCKi) (Tocris). To maximize viability and efficiency, the entire procedure was completed within 20 min.
Transfection efficiency was assessed by nucleofecting 5 μ g of the pmaxGFP vector into another set of cells to monitor GFP expression. For clonal isolation of modified hiPSCs after nucleofection, cultures were dissociated into single cells with Accutase and plated at 1 cell/well in 96-well plates coated with irradiated SNL feeders. Cloned hiPSCs were maintained in hES medium supplemented with 10 μ M ROCKi for 1 week. Single colonies in 96-well plates were passaged into 48-well plates and expanded in 24-well plates. Cells were then harvested for isolation of genomic DNA with a GenElute Mammalian Genomic DNA Miniprep Kit (Sigma), following the manufacturer's instructions. Genomic DNA (250 ng) was amplified by PCR with Phusion High Fidelity DNA Polymerase (Thermo Fisher Scientific) and 0.5 μ M forward and reverse primers flanking the ZFN-binding sequence on APOE to yield a 326-bp fragment. The primer sequences were 5′ -CTCGGCCGCAGGGCGCTGATGGA-3′ (forward) and 5′ -GCCCCGGCCTGGTACACTGCCA-3′ (reverse). The PCR products were sequenced to identify the ZFN-introduced ApoE4 to ApoE3 conversion. The converted ApoE3-encoding isogenic clones were further confirmed by genomic sequencing of the APOE allele covering the donor region and the upstream and downstream regions. The hiPSC lines were karyotyped by Cell Line Genetics.
For immunostaining, hiPSCs that were cultured in 24-well plates were fixed with 4% paraformaldehyde and stained with primary antibodies specific for NANOG (ab21624, Abcam), human nuclei (MAB1281, EMD Millipore), SOX2 (sc-17320, Santa Cruz Biotechnology), OCT3 and OCT4 (sc-5279, Santa Cruz Biotechnology), SSEA4 (ab16287, Abcam), TRA-1-81 (MAB4381, EMD Millipore) and TRA-1-60 (MAB4360, EMD Millipore). The secondary antibodies were Alexa-Fluor-488-or Alexa-Fluor-594-conjugated IgG against rabbit, mouse or goat (catalog no. A-21206, A-21207, A-21202, A-21203, A-11058, A-11055 from Life Technologies) . Nuclei were stained with DAPI. Images were taken with a Leica epifluorescence microscope, a Keyence BZ-9000E fluorescence microscope or a Leica confocal imaging system.
For the teratoma formation assay, 1 × 10 6 cells of each hiPSC line were dissociated with Accutase (Millipore), spun down and resuspended in 100 μ l of PBS. Immunodeficient NOD-SCID mice were anesthetized by standard procedures, and the cell suspensions were injected into the right and left thigh muscles (1 × 10 6 cells per site) of three mice. The mice were monitored during recovery. Tumors were apparent by ~4 weeks. The tumors were collected, fixed, sectioned and stained with hematoxylin and eosin (H&E) to identify teratomas. The protocol was approved by the Animal Care and Use Committees of the Gladstone Institutes and the University of California, San Francisco.
cDNA sequencing of Alzheimer's-disease-related genes. Total RNAs were purified from neurons derived from the parental ApoE4/4 hiPSC and the isogenic ApoE3/3 hiPSC lines using the Qiagen Rneasy mini kit. cDNAs were reversetranscribed from total RNA using oligo(dT) as a primer (SuperScript III FirstStrand Synthesis System, ThermoFisher Scientific). Using the resultant cDNAs as templates, the coding sequence of APP, MAPT (TAU), β -secretase 1 (BACE1) and presenilin 1 (PSEN1; also known as PS1) were amplified with the corresponding two or three pairs of PCR primers. The coding sequence of the NPL4 homolog, ubiquitin recognition factor (NPLOC4) gene was also amplified because it was predicted as a potential off-target gene of the gene-editing approach using the program Prognos. All of the PCR products were then purified and sequenced. The sequencing data were then used to perform BLAST searches for DNA sequence alignment.
Neuronal differentiation of hiPSCs and miPSCs. hiPSCs were differentiated into neurons as described 57, 58 with modifications. hiPSCs were treated with collagenase IV (Stem Cell Technologies) and grown in suspension as embryoid bodies in hES medium without bFGF. The medium was replaced every day for 5 d. On day 5, the embryoid bodies were grown in neural induction medium containing DMEM/ F12 and neurobasal medium (1:1, Thermo Fisher), 1% N2 supplement (Life Technologies), 1% B27 supplement (Life Technologies), non-essential amino acids (NEAA) and 0.5% penicillin-streptomycin (Life Technologies), supplemented with inhibitors of the transforming growth factor (TGF)-β receptor (SB431542, Stemgent; 5 μ M) and the bone morphogenetic protein receptor (LDN-193189, Stemgent; 0.25 μ M). On day 7, spheres were transferred to wells that were coated with Matrigel (BD Biosciences) and grown in neural progenitor medium, which consisted of neural induction medium without SB431542 and LDN-193189, but contained 10 ng/ml bFGF (PeproTech), 10 ng/ml epidermal growth factor (EGF) (PeproTech) and 2 μ g/ml heparin (Sigma). Attached neuroepithelial cells were fed every other day for 7 d. Neural rosette structures appeared by approximately day 15 and were lifted off the plate and grown in suspension in neural progenitor medium to form neurospheres. For neuronal differentiation, neurospheres were dissociated with Accutase and plated on culture plates that were coated with 100 μ g/ml poly-l-ornithine (Sigma) and 10 μ g/ml laminin (Sigma). Neuronal cultures were maintained in neural differentiation medium, which consisted of neural progenitor medium, brain-derived neurotrophic factor (BDNF; 10 ng/ml; PeproTech) and glial-cell-derived growth factor (10 ng/ml; PeproTech) without bFGF, EGF or heparin. Neurons were observed after several days and were further differentiated for 30 d or longer. Most of the experiments were performed on neuronal cultures that had been differentiated > 8 weeks.
miPSCs were differentiated into neurons using a protocol similar to that described above. This culture condition generated 92 ± 3% MAP2 + neurons, including 74 ± 4% vGLUT + total glutamatergic neurons, 32 ± 4% TBR1 + subclass of glutamatergic neurons, 13 ± 3% GABA + GABAergic neurons (for ApoE3/3 miPSCs; 5 ± 2% for ApoE4/4 miPSCs) and 5 ± 2% TH + dopaminergic neurons. In this neuronal culture, GFAP + astrocytes were 3 ± 1%. The percentages of these different cell types generated from miPSCs were very similar to those generated from hiPSCs.
Generation of MGE cells and maturation into GABAergic neurons from hiPSCs. hiPSCs were differentiated into MGE progenitors as previously reported with modifications [26] [27] [28] . On day 1 through day 8 of differentiation, MGE spheres were grown in suspension in KSR medium supplemented with ROCKi, the TGF-β receptor inhibitor SB431542, the Wnt pathway inhibitor Wnt Antagonist II (IWP-II, Millipore), the Hedgehog pathway activator Smoothened Agonist (SAG, Millipore) and the bone morphogenetic protein receptor inhibitor LDN-193189. On day 8, MGE spheres were transferred to KSR medium supplemented with FGF-8 (PeproTech), IWP-II, SAG and LDN-193189. On day 21, MGE progenitors were dissociated with Accutase and plated on culture plates coated with poly-llysine (PLL) overnight at 37 °C and laminin for ≥ 1 h at 37 °C in neural induction medium containing DMEM/F12 and neurobasal medium (1:1, Thermo Fisher), N2 supplement, B27 supplement (Life Technologies), NEAA, Glutamax, and penicillin-streptomycin supplemented with BDNF (PeproTech), glial-derived neurotrophic factor (GDNF, PeproTech), the γ -secretase inhibitor DAPT (Tocris), the MEK-ERK pathway inhibitor SU5402 (STEMCELL Technologies) and the MEK inhibitor PD0325901 (Tocris). From day 28 onward, maturing GABAergic inhibitory interneurons were cultured in neural induction medium containing BDNF and GDNF for up to 5 weeks. 40 and Aβ 42 in the medium from hiPSC-and miPSC-derived neuron cultures. Medium from neuronal cultures was harvested and stored at -80 °C. Cell lysates were collected for normalization with cellular protein amounts and analysis of p-tau levels by western blot analysis. Human and mouse Aβ peptides were measured with MSD Human V-PLEX Aβ Peptide Panel 1 (6E10) Kit (K15200E, Meso Scale Discovery) and Thermo Fisher Mouse Aβ Peptide ELISA Kits (KMB3481 and KMB3441, Thermo Fisher Scientific), respectively, according to the manufacturer's instructions. For human Aβ measurement, the plates were read with a Sector Imager 2400, and the data were acquired and analyzed with Discovery Workbench software. For mouse Aβ measurement, the plates were read with a FlexStation-III, and the data were analyzed with Prism-6 software. For experiments with secretase inhibitors, neuronal cultures were treated with a γ -secretase inhibitor (compound E, Copd-E; at a final concentration of 200 nM), a β -secretase inhibitor (OM99-2, final concentration of 750 nM), or DMSO (vehicle) as described 10 . All inhibitors were from EMD Millipore.
Measurement of Aβ
Astrocyte differentiation of hiPSCs and treatment of neurons from APOEdeficient hiPSCs with astrocyte-conditioned medium. hiPSCs were differentiated into astrocyte progenitors and astrocytes as previously reported with some modifications 59 . The astrocyte progenitors were generated using the procedure as described for neuronal differentiation of hiPSCs. Instead, these progenitor spheres were kept in suspension for further expansion in the presence of 10 ng/ ml bFGF (PeproTech) and 10 ng/ml EGF (PeproTech), and they were passaged by disaggregation into small clusters with a Pasteur pipette for ~90 d. For astroglial differentiation, progenitor spheres were dissociated with Accutase to single cells and seeded onto plates coated with PLL and laminin in neural differentiation medium without bFGF and EGF. The ACM was collected from the astrocyte culture, and the APOE levels in the medium were measured with the Human APOE (AD2) ELISA Kit (cat. no. EHAPOE, Thermo Scientific). The amount of ACM for treatment of the neurons derived from APOE-deficient hiPSCs was adjusted to the same APOE concentration (0.35 nM or 1.47 nM), based on APOE levels in the ACM collected from ApoE3/3 or ApoE4/4 astrocyte culture. After ACM treatment for 1 week, the medium and cell lysates of neurons derived from APOE-deficient hiPSCs were collected and further analyzed.
Treatment of hiPSC-derived neurons with a small-molecule structure corrector. Neuronal cultures derived from hiPSC lines were treated with a smallmolecule structure corrector, PH002 (final concentration, 100 nM; prepared in DMSO) as described [36] [37] [38] . After 7 d of treatment, culture medium was collected for measurement of Aβ 40 and Aβ 42 , and cells were homogenized for western blot analyses. For the dose-effect experiments, different doses of PH002 (i.e., 0 nM, 10 nM, 30 nM and 100 nM) were used to treat the cultured neurons for 1 week.
Treatment of hiPSC-derived neurons with recombinant human APOE.
Neuronal cultures derived from APOE -/-hiPSCs were treated with purified recombinant human ApoE3 or ApoE4 (final concentration, 220 nM or 7.5 μ g/ ml). After 2 d of treatment with recombinant human APOE, culture medium was collected for the measurement of Aβ 40 and Aβ 42 , and cells were homogenized for protein normalization and western blot analysis.
Statistical analyses. Power analysis of a pilot cohort (n = 3) showed that a sample size of three would be sufficient to show genotype effects; all groups had n ≥ 3. Values are expressed as mean ± s.e.m. All n numbers represent the numbers of biological replicates or fields used for image analysis. The distribution of data was assessed with the Shapiro-Wilk normality test; most of the data were normally distributed. The variances between groups were similar as shown by Bartlett's test. Statistical significance was calculated with GraphPad Prism (GraphPad Software). Differences between groups were determined with the unpaired two-sided t-test. For multiple comparisons, ANOVA with Tukey's post-test was used. P < 0.05 was considered to be significant. Researchers were not blinded to the genotypes while performing the experiments.
Compliance with relevant ethical regulations and animal use guidelines. All experimental and animal protocols and procedures were in compliance with the university and institutional ethical regulations and animal use guidelines.
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
Data availability. All of the data generated or analyzed during this study are included in this published article (and its Supplementary Information file) and are available at the corresponding author's lab. Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Experimental design 1. Sample size
Describe how sample size was determined. Power analysis of a pilot cohort (n = 3) showed that a sample size of three would be sufficient to show genotype effects; all groups have n ≥3.
Data exclusions
Describe any data exclusions.
No data were excluded.
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts of replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Samples were randomly allocated to groups.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Investigators were not blinded to apoE genotypes during data collection and/or analysis. Eight hiPSC lines and four miPSC lines with different apoE genotypes were used in this study. Multiple iPSC lines were used in each experiment for differentiating into different types of neurons, and multiple investigators were doing similar experiments. Blinding could easily bring in confusions/mistakes across experiments and among investigators.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
Human skin fibroblasts were used to generated iPSC lines with different apoE genotypes. The general information of subjects from whom skin fibroblasts were collected are presented in Supplementary Table 1. 
